Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC) - Episode 9

Identifying RAI-Refractory Disease: A Key Aspect of DTC Management

Daniel Bowles, MD, leads a discussion on radioactive iodine (RAI) refractory disease, exploring the incidence and resistance levels, and provides recommendations for identifying patient populations who are ineligible for radioiodine treatment.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Differentiated Thyroid Cancer: Examining Key Epidemiological Trends
    EP. 2: Exploring Incidence and Histology of Differentiated Thyroid Cancer
    EP. 3: Determining Prognosis for Patients with Differentiated Thyroid Cancer
    EP. 4: Predisposition for Patients Developing DTC: Age and Gender
    EP. 5: The Role of Molecular Diagnostics in Real-World DTC Management
    EP. 6: Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies
    EP. 7: The Importance of Thyroidectomy in DTC Patient Care
    EP. 8: Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression
    Now Viewing
    EP. 9: Identifying RAI-Refractory Disease: A Key Aspect of DTC Management
    EP. 10: SELECT Trial & DECISION Trial Outcomes and Lessons Learned
    EP. 11: Determining Which DTC Patients May Benefit from Systemic Therapy
    EP. 12: Exploring Real-World Evidence Presented at ATA 2023
    EP. 13: Understanding the Impact of COSMIC-311 and Sequencing in DTC
    EP. 14: Toxicity Profiles for DTC Guidelines Therapies
    EP. 15: Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment
    EP. 16: Neoadjuvant Approach in RAI-R-DTC
    EP. 17: Phase 2 ATLEP Trial Results
    EP. 18: Reflecting on Differentiated Thyroid Cancer: Final Insights
    x